127 related articles for article (PubMed ID: 7724471)
1. Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs.
Igwemezie LN; Kaul S; Barbhaiya RH
Pharm Res; 1995 Jan; 12(1):117-23. PubMed ID: 7724471
[TBL] [Abstract][Full Text] [Related]
2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ
Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162
[TBL] [Abstract][Full Text] [Related]
6. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).
Millward MJ; Newell DR; Mummaneni V; Igwemezie LN; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Eur J Cancer; 1995 Dec; 31A(13-14):2409-11. PubMed ID: 8652278
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacokinetic overview of parenteral etoposide phosphate.
Schacter LP; Igwemezie LN; Seyedsadr M; Morgenthien E; Randolph J; Albert E; Santabárbara P
Cancer Chemother Pharmacol; 1994; 34 Suppl():S58-63. PubMed ID: 8070028
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of etoposide phosphate.
Brooks DJ; Srinivas NR; Alberts DS; Thomas T; Igwemzie LM; McKinney LM; Randolph J; Schacter L; Kaul S; Barbhaiya RH
Anticancer Drugs; 1995 Oct; 6(5):637-44. PubMed ID: 8845473
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
Reif S; Kingreen D; Kloft C; Grimm J; Siegert W; Schunack W; Jaehde U
Cancer Chemother Pharmacol; 2001 Aug; 48(2):134-40. PubMed ID: 11561779
[TBL] [Abstract][Full Text] [Related]
12. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ
J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters.
Mummaneni V; Kaul S; Igwemezie LN; Newell DR; Porter D; Thomas H; Calvert AH; Winograd B; Barbhaiya RH
J Pharmacokinet Biopharm; 1996 Aug; 24(4):313-25. PubMed ID: 9044163
[TBL] [Abstract][Full Text] [Related]
17. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH
Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C
J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK
Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
Herben VM; ten Bokkel Huinink WW; Dubbelman AC; Mandjes IA; Groot Y; van Gortel-van Zomeren DM; Beijnen JH
Br J Cancer; 1997; 76(11):1500-8. PubMed ID: 9400949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
